Other studies predicted that ARID1A is a potential prognostic indicator for hepatocellular carcinoma, possibly through promoting EMT,17 and that loss of expression was linked to pancreatic neuroendocrine tumour metastasis and reduced patient survival time.18 This evidence concerns the gene ARID1A and hepatocellular carcinoma.